Clinical Trial Update: Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating sacituzumab govitecan as neoadjuvant therapy before radical cystectomy for muscle-invasive bladder cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: IRCCS San Raffaele | Conditions: Urothelial Carcinoma | Phase 2 | Status: COMPLETED